TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2236711
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg bupivacaine 0.5%
Study: 2236711
Drug: 7 ml
Normalized name: ethanol 7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml bupivacaine 0.25%
Study: 2236711
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bupivacaine 0.175%
Study: 28795506
Drug: D-4F 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-4F 300 mg
Study: 28795506
Drug: D-4F 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-4F 500 mg
Study: 19382472
Drug: Hydrotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotherapy with Chinese drugs (HT‐C)
Study: 17365264
Drug: Adalimumab (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (either dosage)
Study: 15479320
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA, n = 19)
Study: 11583193
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 on days 1 + 8 of a three-week schedule combined with carboplatin AUC 4 on day 1
Study: 30486656
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention combining cognitive stimulation group and tai chi (14 sessions, twice a week)
Study: 18268065
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) + L-arginine (ARG)
Study: 12460699
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 15 mg/day)
Study: 12460699
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 to 30 mg/day)
Study: 12460699
Drug: Amlodipine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine plus Fosinopril (5/10 to 15/30 mg/day)
Study: 10554808
Drug: Granulocyte‐CSF (G‐CSF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte‐CSF (G‐CSF) + Erythropoietin (EPO)
Study: 8533910
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral famotidine 3 h before induction of anesthesia
Study: 7036291
Drug: Immunostimulation (BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulation (BCG or levamisole) with chemotherapy dimethyl ‐ triazeno ‐ imidazole ‐ carboxamide (DTIC)
Study: 7036291
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents being screened for stage III melanoma
Study: 25083802
Drug: Life Goals
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Goals Collaborative Care (LG‐CC)
Study: 12594140
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine + clonidine
Study: 12594140
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine (control group)
Study: 8816618
Drug: No GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GnRH agonist (control group A)
Study: 1609047
Drug: Haloperidol (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1-3 mg daily)
Study: 1609047
Drug: Thioridazine (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (25-75 mg daily)
Study: 16102903
Drug: LRRK 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRRK 2 G 2019 S mutation screening in Parkinson's disease patients
Study: 16102903
Drug: LRRK 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRRK 2 G 2019 S mutation screening in other neurodegenerative diseases (Alzheimer's, Progressive Supranuclear Palsy, Multiple System Atrophy, frontotemporal dementia)
Study: 12239432
Drug: Beta-carotene content
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene content in oral mucosa epithelium (OMC) in skin type I
Study: 12239432
Drug: Beta-carotene content
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene content in oral mucosa epithelium (OMC) in skin type IV
Study: 2390431
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (20 mg)
Study: 2390431
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (10 mg)
Study: 6291763
Drug: CAM combination
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM combination chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Study: 6291763
Drug: Single‐agent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐agent sequential chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Study: 6291763
Drug: CAM combination
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM combination chemotherapy
Study: 6291763
Drug: Single‐agent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐agent sequential chemotherapy
Study: 6291763
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival for single-agent sequential chemotherapy
Study: 26799573
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance therapy (MRT) - 10 sessions of one hour daily
Study: 26799573
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance therapy (MRT)
Study: 23093256
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg progesterone vaginal gel
Study: 19789415
Drug: Preterax (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterax (2 mg perindopril/0.625 mg indapamide)
Study: 17257820
Drug: NIPSV (noninvasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPSV (noninvasive pressure support ventilation) administered pre‐ and postoperatively for 7 days at home before surgery and 3 days postoperatively
Study: 14982787
Drug: Intravenous dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dalbavancin (single doses starting at 140 mg, escalating to 1120 mg; multiple doses with a 300 mg loading dose followed by six daily 30 mg maintenance doses)
Study: 14982787
Drug: Intravenous dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dalbavancin (various doses)
Study: 9864778
Drug: Short-term corticosteroid
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term corticosteroid therapy (up to 21 days)
Study: 2646350
Drug: Nicergoline, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline, 60 mg daily
Study: 31012562
Drug: Topical test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical test product (peptide combination)
Study: 28679486
Drug: Fibrinogen, von
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen, von Willebrand factor (vWF), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1)
Study: 25727857
Drug: Prolastin-C (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin-C (60 mg/kg) administered weekly over 3 years
Study: 25727857
Drug: Prolastin-C (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin-C (120 mg/kg) administered weekly over 3 years
Study: 25727857
Drug: Prolastin-C (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin-C (60 mg/kg) and Prolastin-C (120 mg/kg)
Study: 23898805
Drug: Integrated Treatment
Normalized name: Bag Spike + Integrated Clave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Treatment (IT) (N=30)
Study: 23898805
Drug: Treatment-as-Usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-Usual (TAU) (N=20)
Study: 19484786
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously on Day 1)
Study: 19484786
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no infusion during ADT)
Study: 16967399
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of dopamine
Study: 631013
Drug: Methadone test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone test dose pupillography
Study: 31533751
Drug: wIRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: wIRA treatment
Study: 31533751
Drug: no-wIRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-wIRA treatment (control group)
Study: 28078599
Drug: Gatifloxacin ophthalmic
Normalized name: gatifloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin ophthalmic solution 0.3%
Study: 25043278
Drug: Low-dose adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adjuvanted sIPV
Study: 19753300
Drug: rIFN‐gamma1b (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma1b (both nebulized and subcutaneous)
Study: 19753300
Drug: Subcutaneous rIFN‐gamma1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rIFN‐gamma1b
Study: 11163560
Drug: Heparin coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coating (general)
Study: 8006914
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of quinapril and hydrochlorothiazide (HCTZ)
Study: 8006914
Drug: Quinapril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril monotherapy
Study: 8006914
Drug: HCTZ monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ monotherapy
Study: 8006914
Drug: Quinapril and
Normalized name: quinapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril and HCTZ combination therapy
Study: 8006914
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg) with HCTZ
Study: 19516176
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tea flavonoids/day
Study: 19516176
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tea flavonoids/day
Study: 19516176
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tea flavonoids/day
Study: 19516176
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tea flavonoids/day
Study: 11479470
Drug: Stenting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting with >=1 heparin-coated stent
Study: 9756247
Drug: Low-energy density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy density (LED) diet (357 kJ/100 g)
Study: 9756247
Drug: High-energy density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy density (HED) diet (629 kJ/100 g)
Study: 7923965
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion without captopril (group I)
Study: 7923965
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion in IgA nephropathy patients (group III)
Study: 7923965
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion in normals without captopril (group I)
Study: 3207855
Drug: Ergoloid mesylates
Normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergoloid mesylates (3-9 mg) administered via oral swallow and sublingual tablets, solution, under fasted and with meal conditions.
Study: 31628121
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout extract (24 mg of activated sulforaphane, twice daily until delivery)
Study: 25973838
Drug: Clipping plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clipping plus epinephrine-saline injection (group B)
Study: 11930309
Drug: RSV immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV immunoglobulin therapy
Study: 8564323
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) as an adjuvant to treatment as usual
Study: 8564323
Drug: Low-dose lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose lithium therapy
Study: 8564323
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance therapy
Study: 2374273
Drug: 420 kcal/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 kcal/d diet for 16 weeks followed by a conventional reducing diet for the remainder of treatment
Study: 949108
Drug: Etomidate infusion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate infusion (2.55 mg/kg)
Study: 24076487
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg bid
Study: 24076487
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg bid
Study: 22713948
Drug: Morphine (0.1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1mg/kg I/M)
Study: 17851042
Drug: 5 to
Normalized name: Hy5 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 to 20 mg/d of oral olanzapine
Study: 15983892
Drug: Multi-drug therapies
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug therapies containing zidovudine, stavudine, or other combinations
Study: 8829023
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of pravastatin
Study: 8829023
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d of probucol and 600 mg/d of pantethine
Study: 8829023
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus exercise therapy
Study: 29692290
Drug: Interviewer‐administered NVS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer‐administered NVS
Study: 22311405
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) with Qinggan Lidan Decoction (QLD) during icteric stage and Yigan Jiangmei Decoction (YJD) in non-icteric hyper-aminotransferase stage, alongside Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks
Study: 22311405
Drug: Ganciclovir 5
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks, with glucurolactone 50 mg three times per day
Study: 17618525
Drug: Ropinirole (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.75 to 15.0 mg/day, mean dose 7.12 mg/day)
Study: 16287635
Drug: Dance movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance movement therapy (DMT)
Study: 12161482
Drug: Raloxifene 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 180 mg/d
Study: 10334649
Drug: 10 mmol/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mmol/d Mg supplement as Mg(OH)2 (approximately 22 mmol Mg/d) for 28 d
Study: 10334649
Drug: Self-selected diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected diet (approximately 11 mmol Mg/d)
Study: 8611062
Drug: Ethanol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.25 g/kg
Study: 8026301
Drug: Ethanol 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.50 g/kg
Study: 8026301
Drug: Ethanol 0.75
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.75 g/kg
Study: 8611062
Drug: Ethanol 0
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0 g/kg (Control)
Study: 8611062
Drug: Ethanol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (all doses)
Study: 29364063
Drug: 7.5% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% sucrose solution (CHO)
Study: 29364063
Drug: Flavour and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavour and taste matched placebo solution (PLA)
Study: 23001190
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of melatonin taken 11 h before baseline sleep midpoint, then 1 h earlier on subsequent days
Study: 21600325
Drug: PTH (1‐34)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH (1‐34) treatment
Study: 17163236
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment in RA patients
Study: 17163236
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment in PsA patients
Study: 11139949
Drug: Sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (320 +/- 20 mg/day)
Study: 11139949
Drug: Propafenone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (450 mg/day)
Study: 27444494
Drug: Cyclizine 50
Normalized name: cyclizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 50 mg (test)
Study: 27444494
Drug: Valoid 50
Normalized name: Valoid 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valoid 50 mg (reference)
Study: 24002927
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of risedronate sodium 35 mg
Study: 24002927
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of risedronate sodium 35 mg
Study: 18641105
Drug: 6.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/kg fospropofol
Study: 18641105
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg fospropofol
Study: 14689224
Drug: Intrarectal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal instillation of lidocaine-prilocain cream (n=75)
Study: 14689224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with sonographic gel intrarectally (n=40)
Study: 9376574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 microg/kg/d filgrastim and 20 microg/kg/d SCF for 7 days
Study: 9376574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 microg/kg/d filgrastim and 25 microg/kg/d SCF for 7 days
Study: 31657712
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg furosemide
Study: 29528807
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy Skills Training Group (DBTSTG)
Study: 29528807
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy Group (CTG)
Study: 29955803
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session)
Study: 26956875
Drug: Compound kushen
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound kushen injection in combination with single-agent chemotherapy
Study: 26956875
Drug: Standard platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard platinum-based doublet chemotherapy
Study: 24607773
Drug: Dual ETA/ETB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ETA/ETB receptor blockade
Study: 12117361
Drug: Donepezil (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (oral administration for a 5-month period)
Study: 9933049
Drug: Doxazosin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (titrated to doses of 2, 4, 8, or 12 mg once daily)
Study: 836384
Drug: Resection treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection treatment (partial duodenopancreatectomy, subtotal left pancreatic resection)
Study: 30869165
Drug: Perampanel 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 2, 4, 8, and 12 mg
Study: 17472017
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (12.5 mg hydrochlorothiazide + 5 mg felodipine)
Study: 17472017
Drug: Monotherapy (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (12.5 mg hydrochlorothiazide + placebo)
Study: 15703092
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (10 ml periprostatic)
Study: 15703092
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (10 ml periprostatic)
Study: 8198930
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg day-1
Study: 8198930
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg day-1
Study: 2836565
Drug: CP at
Normalized name: GLYCERYL ACRYLATE/ACRYLIC ACID COPOLYMER (300000 CP AT 2%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP at 120 mg/m2 over one hour on day 1, plus fluorouracil (5‐FU) at 1,000 mg/m2 over 24 hours as a continuous infusion on days 1 through 5
Study: 2836565
Drug: CP/5‐FU as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP/5‐FU as in A, plus DDTC at 600 mg/m2 over 30 minutes administered IV exactly 30 minutes after CP infusion, plus DDTC at 200 mg/m2 administered IV over 30 minutes on days 8 and 15
Study: 29876770
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (pantoprazole capsules, 40 mg)